Fat-Soluble Vitamins in Standard vs. Liposomal Form Enriched with Vitamin K2 in Cystic Fibrosis: A Randomized Multi-Center Trial

Evaluation of the efficiency of nanomicellar formulation of fat-soluble vitamins in patients with cystic fibrosis: the study protocol for a randomized controlled trial

BACKGROUND

Cystic fibrosis is an inherited disease, which is caused by the CFTR protein defects due to mutations in the CFTR gene. Along with CFTR dysfunction, exocrine pancreatic insufficiency plays a key role in persistent fat malabsorption in CF patients; therefore, deficiency of fat-soluble vitamins (A, D, E, and K) is still a therapeutic challenge. Even with efficient pancreatic enzyme medication and CF-specific vitamins, many patients with CF have fat-soluble vitamins deficiency. The present study aims to evaluate the efficiency of nanomicelle formulation of fat-soluble vitamins in children with CF in order to achieve the appropriate serum levels of these vitamins.

METHODS

This prospective, single-blind control trial will be conducted at the Akbar Children's Hospital in Mashhad, Iran. Patients with CF will be enrolled based on the eligibility criteria. The control group will receive the standard formulation of fat-soluble vitamins similar to the routine CF treatment, and for the intervention group, the nanomicelle formulation of fat-soluble vitamins will be administered for 3 months. The primary outcome of this study is the measurement of serum levels of fat-soluble vitamins. The secondary outcomes are clinical assessment by the Shwachman-Kulczycki score, anthropometrics, and quality of life. Outcomes will be assessed before and after 3 months.

DISCUSSION

Due to persistent fat-soluble vitamin deficiency in CF disease, the nanomicelle formulation could be proposed as a new delivery method of fat-soluble vitamins in the treatment of cystic fibrosis.

TRIAL REGISTRATION

Iranian Registry of Clinical Trials IRCT20220415054541N1. Registered on July 23, 2022.

Combination of Nanodelivery Systems and Constituents Derived from Novel Foods: A Comprehensive Review

Novel Food is a new category of food, regulated by the European Union Directive No. 2015/2283. This latter norm defines a food as "Novel" if it was not used "for human consumption to a significant degree within the Union before the date of entry into force of that regulation, namely 15 May 1997". Recently, Novel Foods have received increased interest from researchers worldwide. In this sense, the key areas of interest are the discovery of new benefits for human health and the exploitation of these novel sources of materials in new fields of application. An emerging area in the pharmaceutical and medicinal fields is nanotechnology, which deals with the development of new delivery systems at a nanometric scale. In this context, this review aims to summarize the recent advances on the design and characterization of nanodelivery systems based on materials belonging to the Novel Food list, as well as on nanoceutical products formulated for delivering compounds derived from Novel Foods. Additionally, the safety hazard of using nanoparticles in food products, i.e., food supplements, has been discussed in view of the current European regulation, which considers nanomaterials as Novel Foods.

Quantification of the Relationship of Pyridoxine and Spirometry Measurements in the United States Population

Background

There has been evidence to suggest associations between vitamins and lung function.

Objective

This study aimed to examine the association between vitamin B6 and spirometry values.

Methods

A cross-sectional study was done using National Health and Nutritional Examination Surveys (NHANES) 2007-2012, which is a nationally representative, modern cohort. Spirometry, a clinical pulmonary function test, measured the amount and speed of air a person could exhale after taking the deepest possible breath after forceful expiratory volume at 1 s (FEV1) and forced vital capacity (FVC). After determination of the relationship of the linearity of variables, univariable and multivariable models were fitted to investigate the effect of vitamin B6 on FEV1 and FVC. The National Center for Health Statistics Ethics Review Board granted permission for the study's data collection and analysis.

Results

Of 19,160 individuals who had complete information on vitamin B6 intake, FEV1, and FVC, it was found each mg of vitamin B6 intake was associated with increase in 166.41 mL of FEV1 (95% CI: 156.71, 176.12; P < 0.01) and 221.6 mL of FVC (95% CI: 209.62, 233.57; P < 0.01). After controlling for potential confounders (age, race, sex, body mass index, education, and income), multiple linear regression found that each mg of vitamin B6 was associated with increase in 25.98 mL of FEV1 (95% CI: 19.15, 32.80, P < 0.01) and 38.97 mL of FVC (95% CI: 30.65, 47.30, P < 0.01).

Conclusion

Increased vitamin B6 intake is associated with improvement in lung function. Further prospective studies are required to ascertain whether increased vitamin B6 can lead to increased long-term spirometry measurements and the specific therapeutic dose-response relationship.

Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing

Cystic fibrosis is a hereditary disease mainly caused by the deletion of the Phe 508 (F508del) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is thus withheld in the endoplasmic reticulum and rapidly degraded by the ubiquitin/proteasome system. Cystic fibrosis remains a potentially fatal disease, but it has become treatable as a chronic condition due to some CFTR-rescuing drugs that, when used in combination, increase in their therapeutic effect due to a synergic action. Also, dietary supplementation of natural compounds in combination with approved drugs could represent a promising strategy to further alleviate cystic fibrosis symptoms. On these bases, we screened by in silico drug repositioning 846 small synthetic or natural compounds from the AIFA database to evaluate their capacity to interact with the highly druggable lumacaftor binding site of F508del-CFTR. Among the identified hits, nicotinamide (NAM) was predicted to accommodate into the lumacaftor binding region of F508del-CFTR without competing against the drug but rather stabilizing its binding. The effective capacity of NAM to bind F508del-CFTR in a lumacaftor-uncompetitive manner was then validated experimentally by surface plasmon resonance analysis. Finally, the capacity of NAM to synergize with lumacaftor increasing its CFTR-rescuing activity was demonstrated in cell-based assays. This study suggests the possible identification of natural small molecules devoid of side effects and endowed with the capacity to synergize with drugs currently employed for the treatment of cystic fibrosis, which hopefully will increase the therapeutic efficacy with lower doses.